Antyproliferacyjne działanie analogów somatostatyny - przesłanie z badania PROMID

Journal Title: OncoReview - Year 2011, Vol 1, Issue 2

Abstract

Authors and Affiliations

Beata Kos-Kudła, Violetta Rosiek

Keywords

Related Articles

Role of molecular examinations in qualification to first line treatment with erlotinib in NSCLC patients based on EURTAC study results

Between 2010–2011 the first EGFR thyrosine kinase inhibitor (EGFR TKI) – gefitinib, was registered in many countries in I line of treatment in patients with advanced and locally advanced non-small cell lung cancer (NSCLC...

Terapia ewerolimusem u pacjenta z zaawansowanym nowotworem neuroendokrynnym trzustki – opis przypadku

Coraz częstsze występowanie nowotworów neuroendokrynnych przewodu pokarmowego jest spowodowane nie tylko rzeczywistym wzrostem zachorowalności, ale także postępem w zakresie ich diagnostyki. Właściwe rozpoznanie oraz oce...

Chemotherapy in gastroenteropancreatic neuroendocrine neoplasm (GEP-NEN)

Approximately two-thirds of malignant GEP-NENs are metastatic at discovery. Chemotherapy with platinum and etoposide is a standard therapy for poorly differentiated GEP-NEC. For well-differentiated pancreatic GEP-NEN ass...

New data concerning treatment of urogenital cancer patients presented at annual congress of American Society of Clinical Oncology 2011

INTRODUCTION: The annual congress of The American Society of Clinical Oncology took place between 03.06.2011 and 06.06.2011 in Chicago, the US.MATERIAL AND METHODS: Papers presented during ASCO are discussed in four sect...

“Life-saving” inappropriate implantable cardioverter-defibrillator shocks in a cancer patient

Impaired left ventricular ejection fraction (LV EF) in patients with cancer can disqualify them from targeted antineoplastic treatment. We present the case of 63-year-old male with gastric cancer treated palliatively, wi...

Download PDF file
  • EP ID EP53103
  • DOI -
  • Views 214
  • Downloads 0

How To Cite

Beata Kos-Kudła, Violetta Rosiek (2011). Antyproliferacyjne działanie analogów somatostatyny - przesłanie z badania PROMID. OncoReview, 1(2), -. https://europub.co.uk./articles/-A-53103